Trinity Health Grand Rapids Family Medicine

Topics

• Hepatocellular Carcinoma Treatment and Prognosis 11
• Genetics, Aging, and Longevity in Model Organisms 5
• Mosquito-borne diseases and control 3
• Aging and Gerontology Research 2
• Cervical Cancer and HPV Research 2
• Disaster Response and Management 2
• Diversity and Career in Medicine 2
• Family and Patient Care in Intensive Care Units 2
• Frailty in Older Adults 2
• Metabolism, Diabetes, and Cancer 2
• Microstructure and Mechanical Properties of Steels 2
• Musculoskeletal Disorders and Rehabilitation 2

Most cited

1. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.

   Hepatology (Baltimore, Md.) · 2025 · 66 citations · Brooke Wietharn

2. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.

   Hepatology (Baltimore, Md.) · 2022 · 215 citations · Brooke Wietharn

3. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.

   Journal of hepatology · 2024 · 69 citations · Brooke Wietharn

4. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.

   European journal of cancer (Oxford, England : 1990) · 2022 · 98 citations · Brooke Wietharn

5. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.

   JAMA oncology · 2024 · 40 citations · Brooke Wietharn

6. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.

   Cancers · 2022 · 71 citations ·